FORMYCON AG announced that the FDA has granted approval for its drug, marking a potential new entry into the market with significant implications for the competitive landscape. The generic drug maker aims to capitalize on the high demand for the branded equivalent, which is expected to inject new revenue streams and challenge current market leaders.